Georgia Memory Net Center for Medicare and Medicaid Services Registry for Anti-Amyloid Monoclonal Antibody Coverage With Evidence Development
Latest Information Update: 12 Mar 2025
At a glance
- Drugs Lecanemab (Primary)
- Indications Alzheimer's disease; Dementia; Mild cognitive impairment
- Focus Therapeutic Use
- 03 Oct 2024 Planned initiation date (estimated date of first participant enrollment) changed from 1 Nov 2023 to 1 Nov 2024.
- 27 Mar 2024 Status changed from not yet recruiting to recruiting.
- 03 Oct 2023 Planned initiation date changed from 1 Sep 2023 to 1 Nov 2023.